Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH Awards $17 Million in Grants to Augment Genomics Research in Africa

Published: Monday, October 21, 2013
Last Updated: Sunday, October 20, 2013
Bookmark and Share
Africa research capacity to be enhanced through expanded H3Africa program.

The National Institutes of Health has awarded 10 new grants totaling up to $17 million over the next four years to support genomics research in Africa, as part of the Human Heredity and Health in Africa (H3Africa) program.

This set of grants is the second disbursement of H3Africa awards and brings the total amount of funding since the 2010 launch of the program to about $74 million.

In addition to genomics research, the new awards will support training of African genomic scientists and building scientific infrastructure on the continent. H3Africa is funded by a partnership between NIH and the United Kingdom's Wellcome Trust.

"These H3Africa awards demonstrate our continued commitment to furthering the capacity for genomics research on the African continent," said Eric D. Green, M.D., Ph.D., director of the National Human Genome Research Institute (NHGRI).

Green continued, "Studying human diseases within populations with the greatest genetic variability and encouraging the contributions of our African colleagues should yield new insights about the role of genetics in health and disease."

The new awards include funding for two additional H3Africa collaborative centers, one that will study the risk factors for stroke and another that will study the role of the human vaginal microbiome in cervical cancer.

New individual research projects will study several other health conditions important in Africa, including neurological disorders, respiratory diseases, fevers of unknown origin, tuberculosis and African sleeping sickness.

Two H3Africa awards will support new biorepository pilot projects. The scaled-up H3Africa biorepositories will house the samples collected through H3Africa research projects and make them available to the entire research community.

In addition, the awards include the first grant being made for an H3Africa ethical, legal, and social implications component.

"We were pleased that the second round of applications for the NIH H3Africa program was of such high quality," said Jane Peterson, Ph.D., project coordinator for H3Africa and senior advisor to the NHGRI Office of the Director.

Peterson continued, "The new awards increase the number of countries participating in H3Africa and expand the range of health conditions being studied. The combined NIH and Wellcome Trust H3Africa program will now support research projects in 27 African countries and 93 collaborators throughout Africa."

"H3Africa is creating new opportunities for collaboration among genomics researchers around Africa and is achieving the program's goal to form a strong backbone of research capacity in Africa," said James Anderson, M.D., Ph.D., director of the NIH Division of Program Coordination, Planning, and Strategic Initiatives, which plans and implements trans-NIH initiatives of the NIH Common Fund, including H3Africa.

H3Africa is a global health program of the NIH Common Fund, and is coordinated by the NHGRI, in partnership with a number of other NIH institutes and offices. These include the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Nerological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the NIH Office of AIDS Research (OAR) and the NIH Office of Research on Women's Health (ORWH).

H3Africa's goals are to enhance the capacity of African researchers to undertake cutting-edge research to advance understanding of the genomic and environmental determinants of common diseases, and in the long run, to use this knowledge to improve the health of African populations.

The newly funded H3Africa grants are awarded in the following categories (pending available funds):

Collaborative Centers

• African Collaborative Center for Microbiome and Genomics Research at the University College Hospital, Ibadan, Nigeria, up to $4.16 million, four-year total
Principal Investigator: Clement Adebamowo, M.D., Sc.D.
Cervical cancer is the most common cancer in Africa. This grant will focus on the epidemiology of cervical cancer and human papillomavirus infection. It addresses a high-impact public health challenge that affects women's health in Africa and the rest of the world. In addition to research, this center will provide post-doctoral training for qualified candidates from across Africa in research methods, epidemiology, bioinformatics, data management and laboratory methods. It also includes study of and training in social and behavioral research, which will be conducted through the Institute of Human Virology and the African University of Science and Technology, both in Nigeria, and the Center for Infectious Diseases Research in Zambia.

• Stroke Investigative Research & Educational Network at the University of Ibadan, Nigeria, up to $2.37 million, four-year total
Principal Investigators: Mayowa Owolabi, M.D. and Bruce Ovbiagele, M.D.
Stroke is the leading cause of neurological hospital admissions in Africa and a leading cause of deaths on the continent. Researchers at this center will evaluate the genetic and environmental risk factors for stroke in Africa, along with training professionals and building research capacity.

Individual Research Projects

• Systems Biology for Molecular Analysis of Tuberculosis in Ethiopia at Addis Ababa University, up to $740,000, four-year total
Principal Investigator: Gobena Ameni, D.V.M., Ph.D.
There are 22 high-tuberculosis-burden countries that account for 80 percent of all active tuberculosis cases, and Ethiopia is one of them. Ethiopian pastoralist groups, in particular, are at increased risk for contracting infection, a recurrence of latent infection, and a high incidence of illness and death due to their high exposure to livestock that potentially increases the level of transmission of tuberculosis between livestock and people. Investigators at Addis Ababa University, in collaboration with scientists at the J. Craig Venter Institute in Rockville, Md., will build genomics capacity at the university to study transmission dynamics, strain diversity and molecular interactions of tuberculosis with its host.

• Host and Microbial Genetic Determinants of Febrile Illness in West Africa, Redeemer's University, Redemption City, Nigeria, up to $1.54 million, four-year total
Principal Investigator: Christian Happi, Ph.D.
Febrile illnesses are among the most common causes of morbidity and mortality in tropical developing countries. In this project, a team of researchers from Nigeria, Senegal, Sierra Leone and the U.S.A. will study the pathogens that cause fevers in rural Africa using new sequencing technologies and microbial metagenomics. This project will also enhance efforts for training, supporting and promoting cutting-edge genomics research on health in Africa through trainings at the Broad Institute and the West African Genomic Research Network sites.

• Clinical and Genetic Studies of Hereditary Neurological Disorders in Mali at University Hospital Center du Point G, Bamako, Mali up to $1.27 million, four-year total
Principal Investigator: Guida Landouré, M.D., Ph.D.
Hereditary neurological disorders are very disabling diseases that are under-studied in Africa. This study aims to clinically characterize these disorders in the Malian population to establish a comprehensive clinical description of the diseases in this region. The study will also identify gene mutations related to neurological diseases and provide training to Malian physicians and students.

• The Nasopharyngeal Microbiome and Respiratory Disease in African Children at the University of Cape Town, South Africa, up to $1.36 million, four-year total.
Principal Investigator: Mark Nicol, Ph.D. and Heather Zar, Ph.D.
Although respiratory infections are a leading cause of morbidity and mortality in young children worldwide, little information is available as to which pathogens colonize the upper airways early in life and how they influence susceptibility or progression to disease. In this study, researchers will collect nasopharyngeal samples from African infants from birth through their first two years of life. They will use culture-independent approaches to identify which viruses and bacteria are present and how changes in colonization patterns and age are associated with the development of pneumonia and wheezing.

• Reprogramming of the Trypanosoma brucei epigenome during human infection: opportunities for new therapies at the University of the Free State, Bloemfontein, South Africa, up to $1.07 million, four-year total
Principal Investigator: Hugh Patterton, Ph.D.
African sleeping sickness is caused by a single-celled trypanosome parasite found in parts of sub-Saharan Africa, and affects hundreds of thousands of individuals. The researchers hope to identify targets for the development of drug treatments by studying changes in the trypanosome's epigenome upon infection. The epigenome of an organism represents elements of inherited information encoded outside of the DNA sequence of its genome.

Ethical, Legal and Social Implications Research Project

• Exploring Perspectives on Genomics and Sickle Cell Public Health Intervention at the University of Cape Town, South Africa, up to $162,000, four-year total
Principal Investigator: Ambroise Wonkam, M.D.
The project will focus on the challenges of implementing genomic research in Africa represented by the psychosocial factors associated with disease burden. Their studies will consider the perspectives of scientists, health professionals, sickle cell disease patients and community populations dealing with the inherited blood disorder. The project will lay the groundwork for more extensive prospective societal implications research.

Pilot Biorepository Research Projects

• Establishment of an H3Africa Biorepository at Clinical Laboratory Services (pilot project) at the University of the Witwatersrand, Johannesburg, South Africa, up to $246,000, two-year total
Principal Investigator: Ute Jentsch, Ph.D., School of Pathology
Clinical Laboratory Services aims to support the H3Africa project by providing services including processing, storing and distributing human samples used in H3Africa research projects.

• Integrated Biorepository of H3Africa Uganda (pilot project) at the Makerere University College of Health Sciences, Kampala, Uganda, up to $236,000, two-year total Principal Investigator: Moses Joloba, Ph.D.
This biorepository will annotate and store biospecimens, making them available for genomic discovery projects by H3Africa Consortium, African and international researchers.

In addition to the Common Fund and NHGRI, management and funding for the new grants are provided by the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD), the National Institute of Neurological Disorders and Stroke (NINDS), the Office of AIDS Research (OAR), and the Office of Research on Women's Health (ORWH).


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
Tuesday, July 21, 2015
NIH Study Identifies Gene Variant Linked to Compulsive Drinking
Mice carrying the Met68BDNF gene variant would consume excessive amounts of alcohol.
Tuesday, July 21, 2015
In Blinding Eye Disease, Trash-Collecting Cells Go Awry, Accelerate Damage
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Friday, July 03, 2015
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Thursday, July 02, 2015
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Tuesday, June 09, 2015
A New Role for Zebrafish: Larger Scale Gene Function Studies
A relatively new method of targeting specific DNA sequences in zebrafish could dramatically accelerate the discovery of gene function and the identification of disease genes in humans.
Monday, June 08, 2015
NIH Researchers Pilot Predictive Medicine by Studying Healthy People’s DNA
New study sequence the genomes of healthy participants to find “putative,” or presumed, mutations.
Friday, June 05, 2015
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
Wednesday, June 03, 2015
Scientists Create Mice with a Major Genetic Cause of ALS and FTD
NIH-funded study provides new platform for testing treatments for several neurodegenerative disorders.
Friday, May 22, 2015
Mice With a Major Genetic Cause of ALS and FTD Created
NIH-funded study provides new platform for testing treatments for several neurodegenerative disorders.
Thursday, May 21, 2015
New Insights into How DNA Differences Influence Gene Activity, Disease Susceptibility
NIH-funded pilot study provides a new resource about variants across the human genome.
Friday, May 08, 2015
Souped-up Remote Control Switches Behaviors On-and-Off in Mice
BRAIN Initiative yields chemical-genetic tool with push-pull capabilities.
Thursday, May 07, 2015
NIH-funded Study Points Way Forward for Retinal Disease Gene Therapy
Benefits for Leber congenital amaurosis peak after one to three years, then diminish.
Tuesday, May 05, 2015
Possible Treatment for Lethal Pediatric Brain Cancer
NIH-funded preclinical study suggests epigenetic drugs may be used to treat leading cause of pediatric brain cancer death.
Tuesday, May 05, 2015
Statement on NIH Funding of Research Using Gene-Editing Technologies in Human Embryos
Researchers modify the gene responsible for a potentially fatal blood disorder using CRISPR/Cas9 technology.
Saturday, May 02, 2015
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!